2022
DOI: 10.3389/fendo.2021.790246
|View full text |Cite
|
Sign up to set email alerts
|

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy

Abstract: BackgroundImmunosuppressive therapy of Graves’ orbitopathy (GO) is indicated during the active phase of disease. Intravenous steroids (IVGC) are effective in about 70% of patients, although unresponsiveness or relapse are observed. In previous studies, rituximab (RTX) has been shown to be effective in inactivating moderate-to-severe GO when used early in the disease, but its optimal dosage has never been studied in randomized clinical trials. Aim of this study was to compare the efficacy and safety of differen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0
5

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 15 publications
(21 citation statements)
references
References 31 publications
0
16
0
5
Order By: Relevance
“…Dosing and route of administration Among the two RCTs, 64% (18/28) patients were treated with a total dose of 2000 mg RTX, the remainder with 500 mg RTX (67,100). A post hoc analysis of three studies from a single center has examined different dosing regimens of RTX in 40 patients and found equivalent rates of disease inactivation and absence of relapse with all doses of RTX (102).…”
Section: Efficacymentioning
confidence: 99%
“…Dosing and route of administration Among the two RCTs, 64% (18/28) patients were treated with a total dose of 2000 mg RTX, the remainder with 500 mg RTX (67,100). A post hoc analysis of three studies from a single center has examined different dosing regimens of RTX in 40 patients and found equivalent rates of disease inactivation and absence of relapse with all doses of RTX (102).…”
Section: Efficacymentioning
confidence: 99%
“…Recently, Campi et al . compared post-hoc different doses of RTX used in patients with GO across three different trials ( 61 ). A total of 40 patients across two open-label prospective studies and one randomized study were treated with 100 mg, 500 mg, and 2 × 1000mg of RTX, respectively.…”
Section: Discussionmentioning
confidence: 99%
“… 67 , 100 A post hoc analysis of three studies from a single center has examined different dosing regimens of RTX in 40 patients and found equivalent rates of disease inactivation and absence of relapse with all doses of RTX. 102 …”
Section: Management Of Moderate-to-severe Tedmentioning
confidence: 99%
“…However, the 100 mg dose failed to lead to disease inactivation or prevent progression to DON in 14% (2/14) patients, and higher doses of RTX were associated with better diplopia outcomes, so the 500 mg was deemed to be optimal. 102 Patients in the two RCTs 67 , 100 were premedicated before receiving RTX using acetaminophen/paracetamol, intravenous hydrocortisone (100 mg) or IVMP (100 mg), and antihistamines. 67 …”
Section: Management Of Moderate-to-severe Tedmentioning
confidence: 99%